Disc Medicine (IRON) posted strong APOLLO Phase 3 bitopertin results in EPP/XLP and plans an end-2026 NDA resubmission.
Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51,966.03.
Disc Medicine reports positive Phase 3 results for bitopertin in EPP, meeting all primary and secondary endpoints. NDA resubmission planned.
Disc Medicine plans to resubmit its blood-disorder drug for FDA approval by year-end after a late-stage trial met all its primary and secondary goals.
U.S. stocks mixed as Dow fell ~100 points; Silence Therapeutics surged 125.7% on Merck KGaA buyout, while biotech and tech shares gained.
Gainers Disc Medicine (NASDAQ:IRON) stock moved upwards by 50.4% to $85.51 during Monday's pre-market session. The company's market cap stands at $2.1 billion. DataMEDS AI (NASDAQ:MEDS) shares moved upwards by
Detailed price information for Harmony Biosciences Holdings Inc (HRMY-Q) from The Globe and Mail including charting and trades.
Disc Medicine is a high-risk sell as bitopertin's steep valuation ignores prior FDA pushback and looming market competition. Learn more about IRON stock here.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
This is the newest page. Registered accounts read further back.